Richard Jenkins at SciMat Custom Case Solution & Analysis

1. Evidence Brief: Business Case Data Researcher

Financial Metrics

Revenue Targets: Corporate headquarters established a 15% annual growth requirement for the Medical Products Division (MPD).
Margin Goals: Jenkins was tasked with increasing operating margins to 22% from the current baseline.
R&D Spending: Historically, MPD allocated 8% of sales to research and development, though output consistency remained unmeasured.
Historical Performance: SciMat experienced three consecutive quarters of declining market share in the core surgical instruments segment prior to Jenkins arrival.

Operational Facts

Reporting Structure: Jenkins oversees five direct reports including functional heads for R&D, Manufacturing, Marketing, Sales, and Finance.
R&D Tenure: Dave Gerson, Head of R&D, has 18 years of tenure at SciMat and operates under a legacy model of high autonomy.
Product Development Cycle: Average time-to-market for new medical devices exceeded 36 months, significantly trailing the industry average of 24 months.
Geographic Scope: Operations are centralized in a single campus, but sales teams are distributed across four domestic regions.

Stakeholder Positions

Richard Jenkins (VP, MPD): Advocates for centralized control, standardized reporting, and rigorous accountability. Views the existing culture as undisciplined.
Dave Gerson (Head of R&D): Believes innovation requires freedom from administrative oversight. Views Jenkins management style as an impediment to creativity.
Billings (CEO): Hired Jenkins specifically to instill discipline but remains sensitive to the loss of key technical talent.
Division Staff: Expressing low morale through exit interviews and internal surveys, citing a lack of trust from new leadership.

Information Gaps

Competitor Benchmarking: The case lacks specific margin and growth data for SciMat primary competitors.
Customer Feedback: There is no direct data from hospital procurement officers regarding SciMat product quality or service levels.
Employee Turnover Rates: Precise percentages for staff departures since Jenkins arrival are not provided.

2. Strategic Analysis: Market Strategy Consultant

Core Strategic Question

How can SciMat synchronize its leadership style with its operational requirements to reverse market share erosion without triggering a mass exodus of R&D talent?

Structural Analysis

Applying the Value Chain lens reveals that the friction between R&D and Executive Leadership has created a bottleneck in the inbound innovation pipeline. The primary activities are stalled because the support activity of Human Resource Management (specifically leadership) is misaligned with the Technical Development requirements of a medical device firm.

The bargaining power of internal talent is high. In the medical products industry, proprietary knowledge resides in individuals rather than processes. Jenkins attempt to commoditize the R&D process ignores the high switching costs associated with replacing specialized engineers.

Strategic Options

Option 1: Enforced Hierarchy and Talent Replacement
Proceed with the current command-and-control model. If Gerson does not comply with new reporting standards, terminate his employment.
Trade-offs: Risk of immediate product development delays vs. long-term gains in operational discipline.
Resource Requirements: Significant budget for executive search and retention bonuses for remaining staff.

Option 2: Operational Decentralization with Financial Centralization
Grant R&D autonomy over creative processes while enforcing strict financial and timeline-based KPIs. Jenkins moves from managing tasks to managing outcomes.
Trade-offs: Preserves culture but may result in slower adoption of standardized corporate processes.
Resource Requirements: Implementation of a sophisticated project management dashboard to monitor progress remotely.

Option 3: Structural Reorganization
Create a separate Advanced Research unit reporting to the CEO, while Jenkins maintains control over Product Engineering and Commercialization.
Trade-offs: Reduces immediate conflict but creates potential silos between research and market needs.
Resource Requirements: Redefinition of P&L responsibilities and organizational charts.

Preliminary Recommendation

SciMat must adopt Option 2. The medical device market rewards innovation speed and technical superiority. Jenkins must shift his focus from how work is done to what is delivered. This preserves the intellectual capital held by Gerson while satisfying the corporate requirement for 15% growth through disciplined milestone tracking.

3. Implementation Roadmap: Operations and Implementation Planner

Critical Path

Phase 1 (Days 1-30): Objective Alignment. Jenkins and Gerson must co-author a single set of success metrics. This removes ambiguity and establishes a shared definition of performance.
Phase 2 (Days 31-60): Governance Transition. Replace daily check-ins with bi-weekly milestone reviews. Shift the focus from activity logs to project health indicators.
Phase 3 (Days 61-90): Talent Stabilization. Conduct one-on-one sessions with the top 20% of R&D staff to communicate the new balanced governance model and address retention risks.

Key Constraints

Leadership Ego: Jenkins must accept that his previous success in different environments may not translate directly to a high-tenure R&D culture.
Institutional Memory: Gerson represents 18 years of technical history. His departure would create an information vacuum that competitors could exploit.
Time Pressure: The 15% growth target is an immediate corporate mandate, leaving little room for a prolonged cultural adjustment period.

Risk-Adjusted Implementation Strategy

The strategy assumes a 20% probability of Gerson resignation regardless of intervention. To mitigate this, Jenkins must identify a deputy within the R&D department who can step in if the relationship fails. Contingency planning involves a phased rollout of new reporting software to avoid overwhelming the staff with administrative changes during peak development cycles.

4. Executive Review and BLUF: Senior Partner

BLUF

Jenkins must pivot from a process-driven to an outcome-driven leadership model immediately. The current path leads to a talent collapse in R&D, which will make the 15% growth target impossible. Retention of Dave Gerson is a strategic necessity, not a management preference. Success requires Jenkins to trade micro-management for macro-accountability. Failure to adjust within 60 days warrants leadership replacement to protect the division P&L.

Dangerous Assumption

The analysis assumes that the 15% growth target is achievable through operational efficiency alone. If the market is saturated or the product pipeline is fundamentally flawed, no amount of management discipline or R&D autonomy will meet the corporate mandate.

Unaddressed Risks

Competitor Poaching (High Probability, High Consequence): Gerson and his team are prime targets for competitors. Every day of internal friction increases the likelihood of a coordinated team departure.
CEO Withdrawal (Medium Probability, Medium Consequence): Billings may lose patience with the internal strife and choose the path of least resistance, which usually involves removing the newcomer (Jenkins) to restore peace.

Unconsidered Alternative

The team failed to consider an external acquisition strategy. If the internal R&D culture is too resistant to change, SciMat could meet its 15% growth target by acquiring smaller, more agile medical tech startups, thereby bypassing the internal bottleneck entirely while Jenkins focuses on optimizing the existing commercial engine.